Modulation of Wnt/β-catenin signaling pathway by bioactive food components

Carcinogenesis

Volumn 33, Issue 3, 2012, Pages 483-491

  Tarapore, Rohinton S ^a,b   Siddiqui, Imtiaz A ^a   Mukhtar, Hasan ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BETA CATENIN; CURCUMIN; DEGUELIN; EPIGALLOCATECHIN GALLATE; FLUOROURACIL; FOLINIC ACID; GENISTEIN; GREEN TEA EXTRACT; ISORHAMNETIN; KAEMPFEROL; LUPEOL; LYCOPENE; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; OXALIPLATIN; PROSTATE SPECIFIC ANTIGEN; RESVERATROL; RETINOID; SULFORAPHANE; TRANSCRIPTION FACTOR PAX3; VITAMIN D; WNT PROTEIN;

AMINO ACID SUBSTITUTION; BROCCOLI; CANCER INHIBITION; CANCER INVASION; CANCER PREVENTION; CANCER RISK; CANCER STAGING; CANCER STEM CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; COLON CANCER; COLORECTAL CANCER; DIETARY INTAKE; EMBRYONIC STEM CELL; EPITHELIAL MESENCHYMAL TRANSITION; EX VIVO STUDY; FOOD COMPOSITION; GENE MUTATION; HEMATOPOIESIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LOSS OF FUNCTION MUTATION; MELANOMA; NEPHROBLASTOMA; NONHUMAN; PHYTOCHEMISTRY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION; TEA; UPREGULATION;

EID: 84857782140     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr305     Document Type: Review

References (217)

1. Sharma, R.P. et al. (1976) Effect of theWingless (wg1)mutation on wing and haltere development in Drosophila melanogaster. Dev. Biol., 48, 461-465.
2. Luu, H.H. et al. (2004) Wnt/beta-catenin signaling pathway as a novel cancer drug target. Curr. Cancer Drug Targets, 4, 653-671.
3. Nusse, R. et al. (1982) Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell, 31, 99-109.
4. Chien, A.J. et al. (2009) AWnt survival guide: from flies to human disease. J. Invest. Dermatol., 129, 1614-1627.
5. Giles, R.H. et al. (2003) Caught up in a Wnt storm: Wnt signaling in cancer. Biochim. Biophys. Acta, 1653, 1-24.
6. Larue, L. et al. (2006) The WNT/Beta-catenin pathway in melanoma. Front. Biosci., 11, 733-742.
7. Behrens, J. (2005) The role of the Wnt signalling pathway in colorectal tumorigenesis. Biochem. Soc. Trans., 33, 672-675.
8. Pezzuto, J.M. (1997) Plant-derived anticancer agents. Biochem. Pharmacol., 53, 121-133.
9. Cragg, G. et al. (1988) Metabolism of plant-derived anticancer agents. Pharmacol. Ther., 37, 425-461.
10. Wang, H.K. (1998) Plant-derived anticancer agents currently in clinical use or in clinical trials. IDrugs, 1, 92-102.
11. Dragsted, L.O. et al. (1993) Cancer-protective factors in fruits and vegetables: biochemical and biological background. Pharmacol. Toxicol., 72 (suppl. 1), 116-135.
12. Ames, B.N. (1983) Dietary carcinogens and anticarcinogens. Oxygen radicals and degenerative diseases. Science, 221, 1256-1264.
13. Surh, Y.J. (2003) Cancer chemoprevention with dietary phytochemicals. Nat. Rev. Cancer, 3, 768-780.
14. Russo, G.L. (2007) Ins and outs of dietary phytochemicals in cancer chemoprevention. Biochem. Pharmacol., 74, 533-544.
15. Khan, N. et al. (2007) Tea polyphenols for health promotion. Life Sci., 81, 519-533.
16. Adhami, V.M. et al. (2003) Molecular targets for green tea in prostate cancer prevention. J. Nutr., 133, 2417S-2424S.
17. Khan, N. et al. (2008) Cancer chemoprevention through dietary antioxidants: progress and promise. Antioxid. Redox Signal., 10, 475-510.
18. Miller, J.R. (2002) The Wnts. Genome Biol., 3, reviews3001.
19. Ozawa, M. et al. (1989) The cytoplasmic domain of the cell adhesion molecule uvomorulin associates with three independent proteins structurally related in different species. EMBO J., 8, 1711-1717.
20. Morin, P.J. (1999) beta-catenin signaling and cancer. Bioessays, 21, 1021-1030.
21. Moon, R.T. (2005) Wnt/beta-catenin pathway. Sci. STKE, 2005, cm1.
22. Liang, H. et al. (2003) Wnt5a inhibits B cell proliferation and functions as a tumor suppressor in hematopoietic tissue. Cancer Cell, 4, 349-360.
23. Uematsu, K. et al. (2003) Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene, 22, 7218-7221.
24. Yasumoto, K. et al. (2002) Microphthalmia-associated transcription factor interacts with LEF-1, a mediator of Wnt signaling. EMBO J., 21, 2703-2714.
25. Saito, H. et al. (2002) Melanocyte-specific microphthalmia-associated transcription factor isoform activates its own gene promoter through physical interaction with lymphoid-enhancing factor 1. J. Biol. Chem., 277, 28787-28794.
26. Dorsky, R.I. et al. (2000) Direct regulation of nacre, a zebrafish MITF homolog required for pigment cell formation, by the Wnt pathway. Genes Dev., 14, 158-162.
27. Shah, K.V. et al. (2008) CTLA-4 is a direct target of Wnt/beta-catenin signaling and is expressed in human melanoma tumors. J. Invest. Dermatol., 128, 2870-2879.
28. Roose, J. et al. (1999) Synergy between tumor suppressor APC and the beta-catenin-Tcf4 target Tcf1. Science, 285, 1923-1926.
29. Filali, M. et al. (2002) Wnt-3A/beta-catenin signaling induces transcription from the LEF-1 promoter. J. Biol. Chem., 277, 33398-33410.
30. Hovanes, K. et al. (2001) Beta-catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer. Nat. Genet., 28, 53-57.
31. van de Wetering, M. et al. (2002) The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell, 111, 241-250.
32. Wu, B. et al. (2007) Wnt signaling induces matrix metalloproteinase expression and regulates T cell transmigration. Immunity, 26, 227-239.
33. Lin, L. et al. (2007) Beta-catenin directly regulates Islet1 expression in cardiovascular progenitors and is required for multiple aspects of cardiogenesis. Proc. Natl Acad. Sci. USA, 104, 9313-9318.
34. Malliri, A. et al. (2006) The rac activator Tiam1 is a Wnt-responsive gene that modifies intestinal tumor development. J. Biol. Chem., 281, 543-548.
35. Kim, T.H. et al. (2005) beta-Catenin activates the growth factor endothelin-1 in colon cancer cells. Oncogene, 24, 597-604.
36. Zhang, X. et al. (2001) Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res., 61, 6050-6054.
37. Tetsu, O. et al. (1999) Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature, 398, 422-426.
38. Shtutman, M. et al. (1999) The cyclin D1 gene is a target of the betacatenin/LEF-1 pathway. Proc. Natl Acad. Sci. USA, 96, 5522-5527.
39. He, T.C. et al. (1998) Identification of c-MYC as a target of the APC pathway. Science, 281, 1509-1512.
40. Lammi, L. et al. (2004) Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer. Am. J. Hum. Genet., 74, 1043-1050.
41. Jho, E.H. et al. (2002) Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol. Cell. Biol., 22, 1172-1183.
42. Lustig, B. et al. (2002) Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. Mol. Cell. Biol., 22, 1184-1193.
43. Yan, D. et al. (2001) Elevated expression of axin2 and hnkd mRNA provides evidence that Wnt/beta -catenin signaling is activated in human colon tumors. Proc. Natl Acad. Sci. USA, 98, 14973-14978.
44. Kahler, R.A. et al. (2003) Lymphoid enhancer factor-1 and beta-catenin inhibit Runx2-dependent transcriptional activation of the osteocalcin promoter. J. Biol. Chem., 278, 11937-11944.
45. Baker, J.C. et al. (1999) Wnt signaling in Xenopus embryos inhibits bmp4 expression and activates neural development. Genes Dev., 13, 3149-3159.
46. Delmas, V. et al. (2007) Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev., 21, 2923-2935.
47. Hecht, A. et al. (2000) The p300/CBP acetyltransferases function as transcriptional coactivators of beta-catenin in vertebrates. EMBO J., 19, 1839-1850.
48. Takemaru, K.I. et al. (2000) The transcriptional coactivator CBP interacts with beta-catenin to activate gene expression. J. Cell Biol., 149, 249-254.
49. Morin, P.J. et al. (1997) Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science, 275, 1787-1790.
50. Rubinfeld, B. et al. (1997) Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science, 275, 1790-1792.
51. Cadigan, K.M. et al. (1998) Wingless repression of Drosophila frizzled 2 expression shapes the Wingless morphogen gradient in the wing. Cell, 93, 767-777.
52. Muller, H.A. et al. (1999) Wingless signaling in the Drosophila embryo: zygotic requirements and the role of the frizzled genes. Development, 126, 577-586.
53. Willert, J. et al. (2002) A transcriptional response to Wnt protein in human embryonic carcinoma cells. BMC Dev. Biol., 2, 8.
54. Wehrli, M. et al. (2000) arrow encodes an LDL-receptor-related protein essential for Wingless signalling. Nature, 407, 527-530.
55. Wharton, K.A. Jr. et al. (2001) Vertebrate proteins related to Drosophila Naked Cuticle bind Dishevelled and antagonize Wnt signaling. Dev. Biol., 234, 93-106.
56. Rousset, R. et al. (2001) Naked cuticle targets dishevelled to antagonize Wnt signal transduction. Genes Dev., 15, 658-671.
57. Spiegelman, V.S. et al. (2000) Wnt/beta-catenin signaling induces the expression and activity of betaTrCP ubiquitin ligase receptor. Mol. Cell, 5, 877-882.
58. Toomes, C. et al. (2004) Mutations in LRP5 or FZD4 underlie the common familial exudative vitreoretinopathy locus on chromosome 11q. Am. J. Hum. Genet., 74, 721-730.
59. Nishisho, I. et al. (1991) Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science, 253, 665-669.
60. Michils, G. et al. (2005) Large deletions of the APC gene in 15% of mutation-negative patients with classical polyposis (FAP): a Belgian study. Hum. Mutat., 25, 125-134.
61. Kinzler, K.W. et al. (1991) Identification of FAP locus genes from chromosome 5q21. Science, 253, 661-665.
62. Kinzler, K.W. et al. (1996) Lessons from hereditary colorectal cancer. Cell, 87, 159-170.
63. Clevers, H. (2006) Wnt/beta-catenin signaling in development and disease. Cell, 127, 469-480.
64. Phelps, R.A. et al. (2009) New perspectives on APC control of cell fate and proliferation in colorectal cancer. Cell Cycle, 8, 2549-2556.
65. Sparks, A.B. et al. (1998) Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res., 58, 1130-1134.
66. Iwao, K. et al. (1998) Activation of the beta-catenin gene by interstitial deletions involving exon 3 in primary colorectal carcinomas without adenomatous polyposis coli mutations. Cancer Res., 58, 1021-1026.
67. Romagnolo, B. et al. (1999) Intestinal dysplasia and adenoma in transgenic mice after overexpression of an activated beta-catenin. Cancer Res., 59, 3875-3879.
68. Miyoshi, Y. et al. (1998) Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res., 58, 2524-2527.
69. Murata, M. et al. (2001) Accumulation of beta-catenin in the cytoplasm and the nuclei during the early hepatic tumorigenesis. Hepatol. Res., 21, 126-135.
70. de La Coste, A. et al. (1998) Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc. Natl Acad. Sci. USA, 95, 8847-8851.
71. Koch, A. et al. (1999)Childhood hepatoblastomas frequently carry amutated degradation targeting box of the beta-catenin gene. Cancer Res., 59, 269-273.
72. Koesters, R. et al. (1999) Mutational activation of the beta-catenin protooncogene is a common event in the development ofWilms' tumors. Cancer Res., 59, 3880-3882.
73. Kusafuka, T. et al. (2002) Codon 45 of the beta-catenin gene, a specific mutational target site of Wilms' tumor. Int. J. Mol. Med., 10, 395-399.
74. Maiti, S. et al. (2000) Frequent association of beta-catenin and WT1 mutations in Wilms tumors. Cancer Res., 60, 6288-6292.
75. Robbins, P.F. et al. (1996) A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med., 183, 1185-1192.
76. Rimm, D.L. et al. (1999) Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. Am. J. Pathol., 154, 325-329.
77. Larue, L. et al. (2003) Beta-catenin in the melanocyte lineage. Pigment Cell Res., 16, 312-317.
78. Lang, D. et al. (2005) Pax3 functions at a nodal point in melanocyte stem cell differentiation. Nature, 433, 884-887.
79. Thomson, J.A. et al. (1995) The brn-2 gene regulates the melanocytic phenotype and tumorigenic potential of human melanoma cells. Oncogene, 11, 691-700.
80. Eisen, T. et al. (1995) The POU domain transcription factor Brn-2: elevated expression in malignant melanoma and regulation of melanocyte-specific gene expression. Oncogene, 11, 2157-2164.
81. Goodall, J. et al. (2004) Brn-2 expression controls melanoma proliferation and is directly regulated by beta-catenin. Mol. Cell. Biol., 24, 2915-2922.
82. Jemal, A. et al. (2009) Cancer statistics, 2009. CA Cancer J. Clin., 59, 225-249.
83. Fearon, E.R. et al. (1990) A genetic model for colorectal tumorigenesis. Cell, 61, 759-767.
84. Munemitsu, S. et al. (1995) Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc. Natl Acad. Sci. USA, 92, 3046-3050.
85. Korinek, V. et al. (1997) Constitutive transcriptional activation by a betacatenin-Tcf complex in APC-/- colon carcinoma. Science, 275, 1784-1787.
86. Kitaeva, M.N. et al. (1997) Mutations in beta-catenin are uncommon in colorectal cancer occurring in occasional replication error-positive tumors. Cancer Res., 57, 4478-4481.
87. Brabletz, T. et al. (2001) Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc. Natl Acad. Sci. USA, 98, 10356-10361.
88. Brabletz, T. et al. (2000) [beta-Catenin induces invasive growth by activating matrix metalloproteinases in colorectal carcinoma]. Verh. Dtsch. Ges. Pathol., 84, 175-181.
89. Hlubek, F. et al. (2007) Heterogeneous expression of Wnt/beta-catenin target genes within colorectal cancer. Int. J. Cancer, 121, 1941-1948.
90. Chesire, D.R. et al. (2000) Detection and analysis of beta-catenin mutations in prostate cancer. Prostate, 45, 323-334.
91. Voeller, H.J. et al. (1998) Beta-catenin mutations in human prostate cancer. Cancer Res., 58, 2520-2523.
92. Gerstein, A.V. et al. (2002) APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers. Genes Chromosomes Cancer, 34, 9-16.
93. Yang, F. et al. (2002) Linking beta-catenin to androgen-signaling pathway. J. Biol. Chem., 277, 11336-11344.
94. Iozzo, R.V. et al. (1995) Aberrant expression of the growth factor Wnt-5A in human malignancy. Cancer Res., 55, 3495-3499.
95. Verras, M. et al. (2006) Roles and regulation of Wnt signaling and betacatenin in prostate cancer. Cancer Lett., 237, 22-32.
96. Truica, C.I. et al. (2000) Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res., 60, 4709-4713.
97. Mulholland, D.J. et al. (2002) The androgen receptor can promote betacatenin nuclear translocation independently of adenomatous polyposis coli. J. Biol. Chem., 277, 17933-17943.
98. Pawlowski, J.E. et al. (2002) Liganded androgen receptor interaction with beta-catenin: nuclear co-localization and modulation of transcriptional activity in neuronal cells. J. Biol. Chem., 277, 20702-20710.
99. Boyden, L.M. et al. (2002) High bone density due to a mutation in LDLreceptor-related protein 5. N. Engl. J. Med., 346, 1513-1521.
100. Little, R.D. et al. (2002) A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am. J. Hum. Genet., 70, 11-19.
101. Little, J.W. (2006) Melanoma: etiology, treatment, and dental implications. Gen. Dent., 54, 61-66.; quiz, 67.
102. Gong, Y. et al. (2001) LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell, 107, 513-523.
103. Robitaille, J. et al. (2002) Mutant frizzled-4 disrupts retinal angiogenesis in familial exudative vitreoretinopathy. Nat. Genet., 32, 326-330.
104. Nikopoulos, K. et al. (2010) Overview of the mutation spectrum in familial exudative vitreoretinopathy and Norrie disease with identification of 21 novel variants in FZD4, LRP5, and NDP. Hum. Mutat., 31, 656-666.
105. Xu, Q. et al. (2004) Vascular development in the retina and inner ear: control by Norrin and Frizzled-4, a high-affinity ligand-receptor pair. Cell, 116, 883-895.
106. Woll, P.S. et al. (2008) Wnt signaling promotes hematoendothelial cell development from human embryonic stem cells. Blood, 111, 122-131.
107. Takahashi-Yanaga, F. et al. (2010) Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin. Cancer Res., 16, 3153-3162.
108. Malizia, A.P. et al. (2009) CUX1/Wnt signaling regulates epithelial mesenchymal transition in EBV infected epithelial cells. Exp. Cell Res., 315, 1819-1831.
109. Sarkar, F.H. et al. (2010) The role of nutraceuticals in the regulation of Wnt and Hedgehog signaling in cancer. Cancer Metastasis Rev., 29, 383-394.
110. Zechner, D. et al. (2003) beta-Catenin signals regulate cell growth and the balance between progenitor cell expansion and differentiation in the nervous system. Dev. Biol., 258, 406-418.
111. Hari, L. et al. (2002) Lineage-specific requirements of beta-catenin in neural crest development. J. Cell Biol., 159, 867-880.
112. Li, Y. et al. (2010) Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin. Cancer Res., 16, 2580-2590.
113. Maund, S.L. et al. (2011) The tissue-specific stem cell as a target for chemoprevention. Stem Cell Rev., 7, 307-314.
114. Lehmann, B. et al. (2010) Conversion of vitamin D3 to hormonally active 1alpha,25-dihydroxyvitamin D3 in cultured keratinocytes: relevance to cell growth and differentiation. J. Steroid Biochem. Mol. Biol., 121, 322-323.
115. Slusarz, A. et al. (2010) Common botanical compounds inhibit the hedgehog signaling pathway in prostate cancer. Cancer Res., 70, 3382-3390.
116. Regenbrecht, C.R. et al. (2008) The molecular basis of genistein-induced mitotic arrest and exit of self-renewal in embryonal carcinoma and primary cancer cell lines. BMC Med. Genomics, 1, 49.
117. Rao, A. et al. (2002) Genistein and vitamin D synergistically inhibit human prostatic epithelial cell growth. J. Nutr., 132, 3191-3194.
118. Kakarala, M. et al. (2010) Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res. Treat, 122, 777-785.
119. Yu, Y. et al. (2009) Elimination of colon cancer stem-like cells by the combination of curcumin and FOLFOX. Transl. Oncol., 2, 321-328.
120. Park, C.H. et al. (2005) Inhibition of beta-catenin-mediated transactivation by flavanone in AGS gastric cancer cells. Biochem. Biophys. Res. Commun., 331, 1222-1228.
121. Androutsopoulos, V.P. et al. (2010) Dietary flavonoids in cancer therapy and prevention: substrates and inhibitors of cytochrome P450 CYP1 enzymes. Pharmacol. Ther., 126, 9-20.
122. Yang, C.S. et al. (2001) Inhibition of carcinogenesis by dietary polyphenolic compounds. Annu. Rev. Nutr., 21, 381-406.
123. Aviram, M. et al. (2002) Pomegranate juice flavonoids inhibit low-density lipoprotein oxidation and cardiovascular diseases: studies in atherosclerotic mice and in humans. Drugs Exp. Clin. Res., 28, 49-62.
124. Stoner, G.D. et al. (1995) Polyphenols as cancer chemopreventive agents. J. Cell. Biochem. Suppl., 22, 169-180.
125. Amado, N.G. et al. (2011) Flavonoids: potential Wnt/beta-catenin signaling modulators in cancer. Life Sci., 89, 545-554.
126. Li, Y. et al. (2008) Regulation of Akt/FOXO3a/GSK-3beta/AR signaling network by isoflavone in prostate cancer cells. J. Biol. Chem., 283, 27707-27716.
127. Sarkar, F.H. et al. (2009) Cellular signaling perturbation by natural products. Cell Signal., 21, 1541-1547.
128. Su, Y. et al. (2009) Soy isoflavone genistein upregulates epithelial adhesion molecule E-cadherin expression and attenuates beta-catenin signaling in mammary epithelial cells. Carcinogenesis, 30, 331-339.
129. Su, Y. et al. (2007) Expression profiling of rat mammary epithelial cells reveals candidate signaling pathways in dietary protection from mammary tumors. Physiol. Genomics, 30, 8-16.
130. Narayan, S. (2004) Curcumin, a multi-functional chemopreventive agent, blocks growth of colon cancer cells by targeting beta-catenin-mediated transactivation and cell-cell adhesion pathways. J.Mol. Histol., 35, 301-307.
131. Wilken, R. et al. (2011) Curcumin: a review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol. Cancer, 10, 12.
132. Zhou, H. et al. (2011) The targets of curcumin. Curr. Drug Targets, 12, 332-347.
133. Epstein, J. et al. (2010) Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. Br. J. Nutr., 103, 1545-1557.
134. Aggarwal, B.B. et al. (2003) Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res., 23, 363-398.
135. Kumar, A. et al. (1998) Curcumin (diferuloylmethane) inhibition of tumor necrosis factor (TNF)-mediated adhesion of monocytes to endothelial cells by suppression of cell surface expression of adhesion molecules and of nuclear factor-kappaB activation. Biochem. Pharmacol., 55, 775-783.
136. Gupta, S.C. et al. (2010) Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev., 29, 405-434.
137. Kelloff, G.J. et al. (1994) Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials. Cancer Res., 54, 2015s-2024s.
138. Kelloff, G.J. et al. (1994) Strategy and planning for chemopreventive drug development: clinical development plans. Chemoprevention Branch and Agent Development Committee. National Cancer Institute. J. Cell. Biochem. Suppl., 20, 55-62.
139. Thomas, S.L. et al. (2010) Activation of the p38 pathway by a novel monoketone curcumin analog, EF24, suggests a potential combination strategy. Biochem. Pharmacol., 80, 1309-1316.
140. Son, M. et al. (2010) Ethanol extract of Lycoris radiata induces cell death in B16F10 melanoma via p38-mediated AP-1 activation. Oncol. Rep., 24, 473-478.
141. Fu, S. et al. (2010) Development of curcumin as an epigenetic agent. Cancer., 116, 4670-4676.
142. Goel, A. et al. (2001) Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells. Cancer Lett., 172, 111-118.
143. Prasad, C.P. et al. (2009) Potent growth suppressive activity of curcumin in human breast cancer cells: modulation of Wnt/beta-catenin signaling. Chem. Biol. Interact., 181, 263-271.
144. Lin, J.K. (2007) Molecular targets of curcumin. Adv. Exp. Med. Biol., 595, 227-243.
145. Jaiswal, A.S. et al. (2002) Beta-catenin-mediated transactivation and cellcell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene, 21, 8414-8427.
146. Ryu, M.J. et al. (2008) Natural derivatives of curcumin attenuate the Wnt/beta-catenin pathway through down-regulation of the transcriptional coactivator p300. Biochem. Biophys. Res. Commun., 377, 1304-1308.
147. Karim, R. et al. (2004) The significance of theWnt pathway in the pathology of human cancers. Pathology, 36, 120-128.
148. Lambert, J.D. et al. (2010) The antioxidant and pro-oxidant activities of green tea polyphenols: a role in cancer prevention. Arch. Biochem. Biophys., 501, 65-72.
149. Tulayakul, P. et al. (2007) The effect of feeding piglets with the diet containing green tea extracts or coumarin on in vitro metabolism of aflatoxin B1 by their tissues. Toxicon, 50, 339-348.
150. Maliakal, P.P. et al. (2001) Tea consumption modulates hepatic drug metabolizing enzymes inWistar rats. J. Pharm. Pharmacol., 53, 569-577.
151. Orner, G.A. et al. (2004) Tumor-suppressing effects of antioxidants from tea. J. Nutr., 134, 3177S-3178S.
152. Carter, O. et al. (2007) Comparison of white tea, green tea, epigallocatechin-3-gallate, and caffeine as inhibitors of PhIP-induced colonic aberrant crypts. Nutr. Cancer, 58, 60-65.
153. Melgarejo, E. et al. (2010) Targeting polyamines and biogenic amines by green tea epigallocatechin-3-gallate. Amino Acids, 38, 519-523.
154. Dashwood, W.M. et al. (2002) Inhibition of beta-catenin/Tcf activity by white tea, green tea, and epigallocatechin-3-gallate (EGCG): minor contribution of H(2)O(2) at physiologically relevant EGCG concentrations. Biochem. Biophys. Res. Commun., 296, 584-588.
155. Kim, J. et al. (2006) Suppression of Wnt signaling by the green tea compound (-)-epigallocatechin 3-gallate (EGCG) in invasive breast cancer cells. Requirement of the transcriptional repressor HBP1. J. Biol. Chem., 281, 10865-10875.
156. Fremont, L. (2000) Biological effects of resveratrol. Life Sci., 66, 663-673.
157. Ulrich, S. et al. (2005) Molecular mechanisms of the chemopreventive effects of resveratrol and its analogs in carcinogenesis. Mol. Nutr. Food Res., 49, 452-461.
158. Baur, J.A. et al. (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov., 5, 493-506.
159. Muriel, P. (2009) NF-kappaB in liver diseases: a target for drug therapy. J. Appl. Toxicol., 29, 91-100.
160. Bishayee, A. (2009) Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev. Res. (Phila)., 2, 409-418.
161. Tsai, S.H. et al. (1999) Suppression of nitric oxide synthase and the downregulation of the activation of NFkappaB in macrophages by resveratrol. Br. J. Pharmacol., 126, 673-680.
162. Pendurthi, U.R. et al. (1999) Resveratrol, a polyphenolic compound found in wine, inhibits tissue factor expression in vascular cells: a possible mechanism for the cardiovascular benefits associated with moderate consumption of wine. Arterioscler. Thromb. Vasc. Biol., 19, 419-426.
163. Roy, P. et al. (2009) Chemopreventive potential of resveratrol in mouse skin tumors through regulation of mitochondrial and PI3K/AKT signaling pathways. Pharm. Res., 26, 211-217.
164. Hope, C. et al. (2008) Low concentrations of resveratrol inhibit Wnt signal throughput in colon-derived cells: implications for colon cancer prevention. Mol. Nutr. Food Res., 52 (suppl. 1), S52-S61.
165. Roccaro, A.M. et al. (2008) Resveratrol exerts antiproliferative activity and induces apoptosis inWaldenstrom's macroglobulinemia. Clin. Cancer Res., 14, 1849-1858.
166. Gatz, S.A. et al. (2008) Resveratrol modulates DNA double-strand break repair pathways in an ATM/ATR-p53- and -Nbs1-dependent manner. Carcinogenesis, 29, 519-527.
167. Saleem, M. (2009) Lupeol, a novel anti-inflammatory and anti-cancer dietary triterpene. Cancer Lett., 285, 109-115.
168. Bani, S. et al. (2006) Suppression of T lymphocyte activity by lupeol isolated from Crataeva religiosa. Phytother. Res., 20, 279-287.
169. Bradford, P.G. et al. (2007) Phytosterols as anticancer compounds. Mol. Nutr. Food Res., 51, 161-170.
170. Fernandez, A. et al. (2001) Anti-inflammatory effect of Pimenta racemosa var. ozua and isolation of the triterpene lupeol. Farmaco, 56, 335-338.
171. Fernandez, M.A. et al. (2001) New insights into the mechanism of action of the anti-inflammatory triterpene lupeol. J. Pharm. Pharmacol., 53, 1533-1539.
172. Geetha, T. et al. (1999) Anticomplement activity of triterpenes from Crataeva nurvala stem bark in adjuvant arthritis in rats. Gen. Pharmacol., 32, 495-497.
173. Lima, L.M. et al. (2007) Anti-inflammatory and analgesic activities of the ethanolic extracts from Zanthoxylum riedelianum (Rutaceae) leaves and stem bark. J. Pharm. Pharmacol., 59, 1151-1158.
174. Molnar, J. et al. (2006) Inhibition of multidrug resistance of cancer cells by natural diterpenes, triterpenes and carotenoids. Curr. Pharm. Des., 12, 287-311.
175. Setzer, W.N. et al. (2003) Plant-derived triterpenoids as potential antineoplastic agents. Mini Rev. Med. Chem., 3, 540-556.
176. Sudhahar, V. et al. (2008) Protective effect of lupeol and lupeol linoleate in hypercholesterolemia associated renal damage. Mol. Cell. Biochem., 317, 11-20.
177. Vasconcelos, J.F. et al. (2008) The triterpenoid lupeol attenuates allergic airway inflammation in a murine model. Int. Immunopharmacol., 8, 1216-1221.
178. Yamashita, K. et al. (2002) Effect of three triterpenoids, lupeol, betulin, and betulinic acid on the stimulus-induced superoxide generation and tyrosyl phosphorylation of proteins in human neutrophils. Clin. Chim. Acta, 325, 91-96.
179. Nigam, N. et al. (2007) Preventive effects of lupeol onDMBA induced DNA alkylation damage in mouse skin. Food Chem. Toxicol., 45, 2331-2335.
180. Prasad, S. et al. (2008) Protective effects of lupeol against benzo[a]pyrene induced clastogenicity in mouse bone marrow cells. Mol. Nutr. Food Res., 52, 1117-1120.
181. Saleem, M. et al. (2004) Lupeol modulates NF-kappaB and PI3K/Akt pathways and inhibits skin cancer in CD-1mice. Oncogene, 23, 5203-5214.
182. Saleem, M. et al. (2008) Lupeol inhibits growth of highly aggressive human metastatic melanoma cells in vitro and in vivo by inducing apoptosis. Clin. Cancer Res., 14, 2119-2127.
183. Saleem, M. et al. (2005) Lupeol, a fruit and vegetable based triterpene, induces apoptotic death of human pancreatic adenocarcinoma cells via inhibition of Ras signaling pathway. Carcinogenesis, 26, 1956-1964.
184. Saleem, M. et al. (2005) A novel dietary triterpene Lupeol induces fasmediated apoptotic death of androgen-sensitive prostate cancer cells and inhibits tumor growth in a xenograft model. Cancer Res., 65, 11203-11213.
185. Lee, T.K. et al. (2007) Lupeol suppresses cisplatin-induced nuclear factorkappaB activation in head and neck squamous cell carcinoma and inhibits local invasion and nodal metastasis in an orthotopic nude mouse model. Cancer Res., 67, 8800-8809.
186. Lira Wde, M. et al. (2008) Modulatory effect of Byrsonima basiloba extracts on the mutagenicity of certain direct and indirect-acting mutagens in Salmonella typhimurium assays. J. Med. Food, 11, 111-119.
187. Saleem, M. et al. (2009) Lupeol inhibits proliferation of human prostate cancer cells by targeting beta-catenin signaling. Carcinogenesis, 30, 808-817.
188. Saleem, M. et al. (2009) Lupeol triterpene, a novel diet-based microtubule targeting agent: disrupts survivin/cFLIP activation in prostate cancer cells. Biochem. Biophys. Res. Commun., 388, 576-582.
189. Tarapore, R.S. et al. (2010) Specific targeting ofWnt/beta-catenin signaling in human melanoma cells by a dietary triterpene lupeol. Carcinogenesis, 31, 1844-1853.
190. Fang, D. et al. (2007) Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J. Biol. Chem., 282, 11221-11229.
191. Hino, S. et al. (2005) Phosphorylation of beta-catenin by cyclic AMPdependent protein kinase stabilizes beta-catenin through inhibition of its ubiquitination. Mol. Cell. Biol., 25, 9063-9072.
192. Taurin, S. et al. (2006) Phosphorylation of beta-catenin by cyclic AMPdependent protein kinase. J. Biol. Chem., 281, 9971-9976.
193. Takahashi-Yanaga, F. et al. (2008) GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy. Cell Signal., 20, 581-589.
194. Soprano, D.R. et al. (2004) Retinoic acid receptors and cancers. Annu. Rev. Nutr., 24, 201-221.
195. Freemantle, S.J. et al. (2003) Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene, 22, 7305-7315.
196. Shah, S. et al. (2002) The role of cadherin, beta-catenin, and AP-1 in retinoid-regulated carcinoma cell differentiation and proliferation. J. Biol. Chem., 277, 25313-25322.
197. Ma, Y. et al. (2005) Retinoid targeting of different D-type cyclins through distinct chemopreventive mechanisms. Cancer Res., 65, 6476-6483.
198. Tang, F.Y. et al. (2008) Lycopene inhibits growth of human colon cancer cells via suppression of the Akt signaling pathway. Mol. Nutr. Food Res., 52, 646-654.
199. Kong, K.W. et al. (2010) Revealing the power of the natural red pigment lycopene. Molecules, 15, 959-987.
200. Musa-Veloso, K. et al. (2009) Influence of observational study design on the interpretation of cancer risk reduction by carotenoids. Nutr. Rev., 67, 527-545.
201. Nahum, A. et al. (2006) Lycopene inhibition of IGF-induced cancer cell growth depends on the level of cyclin D1. Eur. J. Nutr., 45, 275-282.
202. Nahum, A. et al. (2001) Lycopene inhibition of cell cycle progression in breast and endometrial cancer cells is associated with reduction in cyclin D levels and retention of p27(Kip1) in the cyclin E-cdk2 complexes. Oncogene, 20, 3428-3436.
203. Hung, C.F. et al. (2008) Lycopene inhibits TNF-alpha-induced endothelial ICAM-1 expression and monocyte-endothelial adhesion. Eur. J. Pharmacol., 586, 275-282.
204. Murillo, G. et al. (2009) Deguelin inhibits growth of breast cancer cells by modulating the expression of key members of the Wnt signaling pathway. Cancer Prev. Res. (Phila)., 2, 942-950.
205. Gerhauser, C. et al. (1995) Rotenoids mediate potent cancer chemopreventive activity through transcriptional regulation of ornithine decarboxylase. Nat. Med., 1, 260-266.
206. Peng, X.H. et al. (2007) Down-regulation of inhibitor of apoptosis proteins by deguelin selectively induces apoptosis in breast cancer cells. Mol. Pharmacol., 71, 101-111.
207. Lee, H.Y. et al. (2005) Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis. J. Natl Cancer Inst., 97, 1695-1699.
208. Murillo, G. et al. (2002) Deguelin inhibits the growth of colon cancer cells through the induction of apoptosis and cell cycle arrest. Eur. J. Cancer, 38, 2446-2454.
209. Murillo, G. et al. (2003) Deguelin suppresses the formation of carcinogeninduced aberrant crypt foci in the colon of CF-1 mice. Int. J. Cancer, 104, 7-11.
210. Kim, W.Y. et al. (2009) Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor-1alpha. Cancer Res., 69, 1624-1632.
211. Zhang, Y. et al. (1994) Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates. Proc. Natl Acad. Sci. USA, 91, 3147-3150.
212. Chung, F.L. et al. (2000) Chemoprevention of colonic aberrant crypt foci in Fischer rats by sulforaphane and phenethyl isothiocyanate. Carcinogenesis, 21, 2287-2291.
213. Kassie, F. et al. (2003) Chemoprevention of 2-amino-3-methylimidazo[4,5-f]quinoline (IQ)-induced colonic and hepatic preneoplastic lesions in the F344 rat by cruciferous vegetables administered simultaneously with the carcinogen. Carcinogenesis, 24, 255-261.
214. Fahey, J.W. et al. (2002) Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. Proc. Natl Acad. Sci. USA, 99, 7610-7615.
215. Hecht, S.S. et al. (2002) Benzyl isothiocyanate: an effective inhibitor of polycyclic aromatic hydrocarbon tumorigenesis in A/J mouse lung. Cancer Lett., 187, 87-94.
216. Jackson, S.J. et al. (2004) Sulforaphane: a naturally occurring mammary carcinoma mitotic inhibitor, which disrupts tubulin polymerization. Carcinogenesis, 25, 219-227.
217. Hu, R. et al. (2006) Cancer chemoprevention of intestinal polyposis in ApcMin/+ mice by sulforaphane, a natural product derived from cruciferous vegetable. Carcinogenesis, 27, 2038-2046.